A. Benjamin Suttle - Concepedia

Author

A. Benjamin Suttle

Research Triangle Park Foundation

Also Known As

A B Suttle, A. B. Suttle, A. Benjamin Suttle, A. Benjamin. Suttle, A. Suttle, A.B. Suttle, AB Suttle

Publications

2.3K

Citations

H-Index

Concepts

All Affiliations

Research Triangle Park Foundation GlaxoSmithKline (United States)GlaxoSmithKline (Netherlands)Sarah Cannon Case Western Reserve University

About

A. Benjamin Suttle is an author at Research Triangle Park Foundation specializing in medicine, oncology, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	14	16	492
2	Pathology	6	6	135
3	Health Sciences	3	3	56
4	Cell Biology	1	1	19
5	Hepatology	1	1	21

A. Benjamin Suttle

Publications

2.2K

Citations

H-Index

Page 1

	Year	Citations
The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia Eytan M. Stein, Guillermo Garcia‐Manero, David A. Rizzieri, Blood	2018	442
Phase I Trial of Pazopanib in Patients with Advanced Cancer Herbert I. Hurwitz, Afshin Dowlati, Shermini Saini, Clinical Cancer Research	2009	411
Relationships between pazopanib exposure and clinical safety and efficacy in patients with advanced renal cell carcinoma A. Benjamin Suttle, Howard Ball, Mathiéu Molimard, British Journal of Cancer	2014	180
A Phase I/II Trial of Pazopanib in Combination with Lapatinib in Adult Patients with Relapsed Malignant Glioma David A. Reardon, Morris D. Groves, Patrick Y. Wen, Clinical Cancer Research	2013	123
Effects of ketoconazole and esomeprazole on the pharmacokinetics of pazopanib in patients with solid tumors Antoinette R. Tan, Darlene Gibbon, Mark N. Stein, Cancer Chemotherapy and Pharmacology OncologySolid TumorsPharmacologyPharmacotherapyAnti-cancer Agent	2013	105
A Phase I Study of the Pharmacokinetic and Safety Profiles of Oral Pazopanib With a High-Fat or Low-Fat Meal in Patients With Advanced Solid Tumors Elisabeth I. Heath, E. Gabriela Chiorean, Christopher J. Sweeney, Clinical Pharmacology & Therapeutics	2010	98
Phase I Dose-Finding Study of Pazopanib in Hepatocellular Carcinoma: Evaluation of Early Efficacy, Pharmacokinetics, and Pharmacodynamics Thomas Yau, Pei‐Jer Chen, Pierre Chan, Clinical Cancer Research	2011	88
Bioavailability, metabolism and disposition of oral pazopanib in patients with advanced cancer Yanli Deng, Caroline Sychterz, A. Benjamin Suttle, Xenobiotica	2012	83
An Evaluation of the Drug Interaction Potential of Pazopanib, an Oral Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, Using a Modified Cooperstown 5+1 Cocktail in Patients With Advanced Solid Tumors Brian C. Goh, Nandi J. Reddy, Uday B. Dandamudi, Clinical Pharmacology & Therapeutics	2010	82
Use of a Pharmacokinetic Model Incorporating Discontinuous Gastrointestinal Absorption to Examine the Occurrence of Double Peaks in Oral Concentration–Time Profiles A. Benjamin Suttle, Gary M. Pollack, Kim L. R. Brouwer Pharmaceutical Research	1992	58

Page 1